• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Roche's closely watched immunotherapy fails key study in tough-to-treat lung cancer

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 30, 2022 at 11:12: AM
via A drug combination including the Roche immunotherapy tiragolumab failed a Phase 3 trial in a tough-to-treat form of lung cancer, a setback for a closely watched group of medicines that work by targeting a protein called TIGIT.

article source
 




Top Bottom
Back
Quote